All In Biotech

Free tool

FAERS Monitor: Argatroban

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201811 or its brand name (Argatroban, Argatroban). Reports on generic versions are filed under their own applications.

Reports

1,499

Serious

1,309

87% of reports

Hospitalization

637

Death reported

321

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • heparin-induced thrombocytopenia191
  • drug ineffective157
  • international normalised ratio increased110
  • off label use99
  • activated partial thromboplastin time prolonged83
  • haemorrhage81
  • pulmonary embolism70
  • thrombocytopenia70
  • deep vein thrombosis69
  • coagulation time prolonged64
  • thrombosis56
  • gastrointestinal haemorrhage54
  • cerebral infarction50
  • platelet count decreased39
  • cerebral haemorrhage38

Reports by year received

View as table
YearReports
200420
200522
200642
200764
200848
200947
2010195
201199
201274
201339
201443
201547
201632
201768
201853
201987
202086
202194
202292
202369
202461
202583
202634

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,660 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
coagulation time prolongedSignal64605.3473.736,441
heparin-induced thrombocytopeniaSignal191565.8494.1102,999
activated partial thromboplastin time prolongedSignal83233.8189.418,704
international normalised ratio increasedSignal11054.345.45,692
cerebral infarctionSignal5028.821.91,312
deep vein thrombosisSignal6914.911.8884
cerebral haemorrhageSignal3814.910.9480
haemorrhageSignal8110.98.8720
pulmonary embolismSignal7010.38.2584
thrombosisSignal569.87.6434
gastrointestinal haemorrhageSignal549.17.0381
thrombocytopeniaSignal708.87.0478
platelet count decreasedSignal395.13.8126
drug ineffective1571.71.444
off label use991.61.322

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.